Circulating prostacyclin concentrations may be increased by bendrofluazide in patients with essential hypertension.
1. A within-patient randomized double-blind crossover study was performed on mechanisms of action of bendrofluazide in mild essential hypertension. Significant reductions in lying, standing and post-exercise blood pressure were seen after both 3 days and 10 weeks treatment with bendrofluazide (10 mg daily). 2. Plasma levels of 6-oxo-prostaglandin F1 alpha, the chemical hydrolysis product of prostacyclin, were significantly increased by both 3 days and 10 weeks therapy with bendrofluazide. This raises the possibility that thiazides may reduce peripheral resistance by increasing prostacyclin biosynthesis.
D001539:Bendroflumethiazide / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D011464:Epoprostenol / Q000097:blood*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D009638:Norepinephrine; D011453:Prostaglandins / Q000097:blood*; D011460:Prostaglandins F / Q000097:blood; D012083:Renin / Q000097:blood
D011453:Prostaglandins; D011460:Prostaglandins F; D001539:Bendroflumethiazide; D011464:Epoprostenol; D012083:Renin; D009638:Norepinephrine